Cue Biopharma, Inc. – NASDAQ:CUE
Cue Biopharma stock price today
$0.81
-0.22
-22.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Cue Biopharma stock price monthly change
+10.62%
month
Cue Biopharma stock price quarterly change
+10.62%
quarter
Cue Biopharma stock price yearly change
-64.01%
year
Cue Biopharma key metrics
Market Cap | 62.08M |
Enterprise value | 78.57M |
P/E | -2.22 |
EV/Sales | 34.59 |
EV/EBITDA | -1.01 |
Price/Sales | 48.81 |
Price/Book | 1.68 |
PEG ratio | 0.39 |
EPS | -1.06 |
Revenue | 7.02M |
EBITDA | -46.61M |
Income | -49.97M |
Revenue Q/Q | 818.18% |
Revenue Y/Y | 1524.14% |
Profit margin | -3543.17% |
Oper. margin | -3558.02% |
Gross margin | 0% |
EBIT margin | -3558.02% |
EBITDA margin | -663.96% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCue Biopharma stock price history
Cue Biopharma stock forecast
Cue Biopharma financial statements
Average Price Target
$4
Potential upside: 393.76%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.38M | -13.18M | -954.05% |
|---|---|---|---|
| Sep 2023 | 2.1M | -11.00M | -524.05% |
| Dec 2023 | 1.82M | -13.43M | -737.73% |
| Mar 2024 | 1.71M | -12.34M | -719.1% |
| Jun 2023 | 73163000 | 27.15M | 37.12% |
|---|---|---|---|
| Sep 2023 | 68888000 | 26.22M | 38.06% |
| Dec 2023 | 61530000 | 24.44M | 39.73% |
| Mar 2024 | 53951000 | 23.91M | 44.32% |
| Jun 2023 | -10.37M | 5M | 2.10M |
|---|---|---|---|
| Sep 2023 | -7.79M | 5M | 4.58M |
| Dec 2023 | -10.95M | 0 | 4.78M |
| Mar 2024 | -9.78M | -55K | 2.35M |
Cue Biopharma alternative data
| Aug 2023 | 51 |
|---|---|
| Sep 2023 | 51 |
| Oct 2023 | 51 |
| Nov 2023 | 51 |
| Dec 2023 | 51 |
| Jan 2024 | 51 |
| Feb 2024 | 51 |
| Mar 2024 | 51 |
| Apr 2024 | 51 |
| May 2024 | 53 |
| Jun 2024 | 53 |
| Jul 2024 | 53 |
Cue Biopharma other data
16.74%
-19.32%
of CUE is owned by hedge funds
38
-21
5.96M
-6.79M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2024 | 30000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PASSERI DANIEL R director, officer: CHIEF EXECUT.. | Common Stock | 30,000 | $1.03 | $30,900 | ||
Purchase | SURI ANISH officer: PRESIDEN.. | Common Stock | 4,000 | $2.76 | $11,040 | ||
Purchase | PASSERI DANIEL R director, officer: CHIEF EXECUT.. | Common Stock | 3,000 | $2.86 | $8,580 | ||
Option | KIENER PETER A director | Stock Option (right to buy) | 9,682 | $2.86 | $27,691 | ||
Sale | KIENER PETER A director | Common Stock | 9,325 | $3.28 | $30,586 | ||
Option | KIENER PETER A director | Common Stock | 9,682 | $2.86 | $27,691 | ||
Option | MILLAR KERRI-ANN officer: CHIEF FI.. | Restricted Stock Units | 6,667 | N/A | N/A | ||
Option | MILLAR KERRI-ANN officer: CHIEF FI.. | Common Stock | 6,667 | N/A | N/A | ||
Purchase | MORICH FRANK director | Common Stock | 28,000 | $3.75 | $105,000 | ||
Purchase | FLETCHER AARON G.L. director | Common Stock | 55,000 | $3.34 | $183,700 |
| Patent |
|---|
Grant Filling date: 18 Jan 2022 Issue date: 5 Jul 2022 |
Grant Filling date: 21 Oct 2021 Issue date: 28 Jun 2022 |
Application Filling date: 18 Jan 2022 Issue date: 9 Jun 2022 |
Application Filling date: 25 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 7 Sep 2021 Issue date: 5 May 2022 |
Application Filling date: 7 Sep 2021 Issue date: 5 May 2022 |
Application Filling date: 24 Aug 2021 Issue date: 21 Apr 2022 |
Application Filling date: 21 May 2021 Issue date: 14 Apr 2022 |
Application Filling date: 5 Aug 2021 Issue date: 7 Apr 2022 |
Application Filling date: 8 Jun 2021 Issue date: 17 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2023 8 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 21 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Daniel R. Passeri M.Sc., MSc., J.D. (1961) Chief Executive Officer & Director | $751,550 |
| Dr. Anish Suri Ph.D. (1974) Pres & Chief Scientific Officer | $583,690 |
| Ms. Kerri-Ann Millar (1970) Chief Financial Officer | $404,650 |
-
What's the price of Cue Biopharma stock today?
One share of Cue Biopharma stock can currently be purchased for approximately $0.81.
-
When is Cue Biopharma's next earnings date?
Unfortunately, Cue Biopharma's (CUE) next earnings date is currently unknown.
-
Does Cue Biopharma pay dividends?
No, Cue Biopharma does not pay dividends.
-
How much money does Cue Biopharma make?
Cue Biopharma has a market capitalization of 62.08M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 340.88% to 5.49M US dollars.
-
What is Cue Biopharma's stock symbol?
Cue Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "CUE".
-
What is Cue Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cue Biopharma?
Shares of Cue Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cue Biopharma's key executives?
Cue Biopharma's management team includes the following people:
- Mr. Daniel R. Passeri M.Sc., MSc., J.D. Chief Executive Officer & Director(age: 64, pay: $751,550)
- Dr. Anish Suri Ph.D. Pres & Chief Scientific Officer(age: 51, pay: $583,690)
- Ms. Kerri-Ann Millar Chief Financial Officer(age: 55, pay: $404,650)
-
How many employees does Cue Biopharma have?
As Jul 2024, Cue Biopharma employs 53 workers, which is 4% more then previous quarter.
-
When Cue Biopharma went public?
Cue Biopharma, Inc. is publicly traded company for more then 7 years since IPO on 2 Jan 2018.
-
What is Cue Biopharma's official website?
The official website for Cue Biopharma is cuebiopharma.com.
-
Where are Cue Biopharma's headquarters?
Cue Biopharma is headquartered at 21 Erie Street, Cambridge, MA.
-
How can i contact Cue Biopharma?
Cue Biopharma's mailing address is 21 Erie Street, Cambridge, MA and company can be reached via phone at +61 79492680.
-
What is Cue Biopharma stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Cue Biopharma in the last 12 months, the avarage price target is $4. The average price target represents a 393.76% change from the last price of $0.81.
Cue Biopharma company profile:
Cue Biopharma, Inc.
cuebiopharma.comExchange:
NASDAQ
Full time employees:
53
Industry:
Biotechnology
Sector:
Healthcare
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
21 Erie Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001645460
ISIN: US22978P1066
CUSIP: 22978P106
